Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Implementing an IGRA (interferon-gamma release assay) based TB screening pathway prior to starting biological treatments – Experience from a UK university hospital

Subashini Chandrapalan, Ashwin Rajhan, Sven Lehm, Sarah Goddard, Amanda Middleton
European Respiratory Journal 2016 48: PA2743; DOI: 10.1183/13993003.congress-2016.PA2743
Subashini Chandrapalan
1Department of Respiratory Medicine, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashwin Rajhan
1Department of Respiratory Medicine, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sven Lehm
1Department of Respiratory Medicine, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Goddard
2Department of Immunology, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda Middleton
1Department of Respiratory Medicine, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Introduction: The use of Anti-TNF alpha is increasing recently. In 2011 NICE recommended using IGRA for detecting latent TB. However there is uncertainty around the sensitivity of IGRA in immunosuppressed patients as well as regarding implementation of screening pathways.

Methods: In 2013 we implemented a TB screening pathway in collaboration with various departments in our hospital that use biological treatments.

IGRA is requested pre-biologics in patients with no evidence of active TB. If IGRA is positive or intermediate twice, patients are referred to the TB service. If negative, in patients on immunosuppression, epidemiological TB risk stratification is undertaken and high risk patients are referred to the TB service.

Retrospective analysis of 209 IGRA requests pre-biologics was done from Apr 14 – Mar 15

Results: Of the 175 patients with the negative results, 10 patients were of high epidemiological risk - 5 were on immunosupressants and of these 4 were referred to the TB services.

Of the 7 patients with positive results, five patients were referred and managed appropriately and two patients were not referred.

Of the 18 patients with indeterminate results, 12 patients had the test repeated. 8 patients had indeterminate results again and were referred. 3 patients were started on prophylaxis.

Conclusions: A TB screening pathway pre-starting biological treatment can be successfully implemented in collaboration with various departments.

Uncertainty remains regarding the sensitivity of IGRA in immunosuppression. However using a referral pathway for high risk, IGRA negative patients to TB services by defined criteria is feasible.

  • IGRA (Interferon gamma)
  • Immunosuppression
  • Immunology
  • Copyright ©the authors 2016
Previous
Back to top
Vol 48 Issue suppl 60 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Implementing an IGRA (interferon-gamma release assay) based TB screening pathway prior to starting biological treatments – Experience from a UK university hospital
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Implementing an IGRA (interferon-gamma release assay) based TB screening pathway prior to starting biological treatments – Experience from a UK university hospital
Subashini Chandrapalan, Ashwin Rajhan, Sven Lehm, Sarah Goddard, Amanda Middleton
European Respiratory Journal Sep 2016, 48 (suppl 60) PA2743; DOI: 10.1183/13993003.congress-2016.PA2743

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Implementing an IGRA (interferon-gamma release assay) based TB screening pathway prior to starting biological treatments – Experience from a UK university hospital
Subashini Chandrapalan, Ashwin Rajhan, Sven Lehm, Sarah Goddard, Amanda Middleton
European Respiratory Journal Sep 2016, 48 (suppl 60) PA2743; DOI: 10.1183/13993003.congress-2016.PA2743
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Indicators of rifampicin-resistant TB response in Belarus, 2009-2014
  • MDR-TB: Early screening or future screaming
  • Prospective study analysing prevalence of XDR TB in Mumbai, India
Show more 10.2 Tuberculosis

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society